查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1190626

DNA 测序市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Dna Sequencing Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 131 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2021 年 DNA 测序市场价值约为 104.954 亿美元，到 2027 年将达到 238.8565 亿美元，预计在预测期内（2022-2027 年）复合年增长率为 18.61%。

COVID-19 大流行对研究中的市场产生了积极影响，因为它增加了治疗和诊断开发中对 DNA 测序技术的需求。 例如，2020 年 8 月，Helix COVID-19 NGS 测试获得了 FDA 的紧急使用授权（EUA）批准，仅适用于 Helix Laboratories。 这是一种基于扩增子的下一代测序 (NGS) 测试，用于定性检测疑似 COVID-19 感染者的上呼吸道标本中的 SARS-CoV-2 核酸。 因此，由于在开发 COVID-19 的诊断工具和有效治疗方法中基于 DNA 测序的研发活动不断增加，预计市场在预测期内将保持显着增长率。

推动市场增长的某些因素包括 DNA 测序技术的进步、临床诊断和药物发现应用的增加，以及研发投资的增加。 DNA 测序在诊断学、个性化医疗、生物标誌物、法医学、生殖医学等方面都有应用。 ] DNA测序技术在癌症诊断和治疗的临床研究和开发中具有巨大的潜力。 近年来，下一代测序 (NGS) 技术已证明其作为一种高通量且廉价的方法能够在单次测试中识别和表征大量基因的临床可操作遗传改变。 根据Hong-Yan Liu等人发表于Scientific Reports Journal 2019的研究论文，估计80%的罕见病是由基因引起的，因此基于基因组测序的诊断是罕见病管理的重要工具。它提供了一个有前途的替代方案，预计将对市场产生积极影响。 因此，预计 DNA 测序在临床诊断和药物发现中的应用越来越多，将在预测期内推动市场增长。

从 20 世纪 70 年代的二维测序到 DNA 测序，测序技术取得了长足的进步。 近年来，Illumina/Solexa、ABI/SOLiD、454/Roche 和 Helicos 等平台为高通量功能基因组学研究提供了独特的视角。 此外，生物学家和信息学专业人士专注于开发更好的基因组，新的测序技术、识别染色体序列的新方法以及 DNA 测序软件的改进使之成为可能。我猜

新一代测序 (NGS) 技术作为常规临床诊断测试也越来越受欢迎，尤其是在 COVID-19 大流行期间，它对市场产生了积极影响。 因此，DNA 测序技术的不断进步正在促进调查市场的增长。

主要市场趋势

下一代测序领域有望在预测期内主导市场

下一代测序领域的驱动因素包括 NGS 应用的增加、速度、成本、准确性、传统技术的有效替代方案，以及需要 NGS 技术的药物发现应用。 这项技术的优势在于它更便宜、更快并且需要更少的 DNA，从而有助于整个细分市场的增长。

COVID-19 大流行增加了下一代测序技术在传染病诊断中的应用，因为它具有高效率和准确性。 2020 年 6 月，FDA 为其产品 COVIDSeq 测试授予 Illumina 紧急使用授权，这是第一个利用下一代测序技术的 COVID-19诊断测试。 使用二代测序进行检测的优势在于，它可以检测样本中是否存在病毒，同时生成有关样本中病毒基因组序列的信息。 该基因组信息可用于研究目的，从而支持市场增长。

医疗领域拥有各种技术进步并且正在快速发展，导致个性化医疗的发展。 下一代测序在个性化医疗中的应用数量巨大。 2020 年 5 月，瑞典生物技术公司 CARTANA 扩展了其用于高通量单细胞基因表达图谱的原位测序试剂盒系列。 2020 年 10 月，Bio-Rad Laboratories Inc. 宣布推出 SEQuoia Complete Stranded RNA Library Prep Kit，这是一种新的 RNA-Seq 文库製备方法。 因此，个性化医疗的进步为 NGS 应用开闢了许多途径，并可能加速该领域的发展。

推出和改进，以及对这项技术的好处和不断增长的需求，是细分市场增长的主要驱动力。 例如，Thermo Fisher Scientific 于 2019 年 11 月推出了 Ion Torrent Genexus 系统。 它是第一个完全集成的下一代测序 (NGS) 平台，具有自动化的样本到报告工作流程，可在一天内提供经济的结果。 因此，由于上述因素，预计该细分市场将在预测期内增长。

北美主导市场，预计在预测期内也会如此

由于政府和非政府组织（尤其是在美国）增加的资金和宣传，北美在市场上占据主导地位。 越来越多地采用先进技术以及政府和相关政策的有利支持是该国 DNA 测序的主要驱动力。

COVID-19 大流行病的兴起也对市场增长产生了积极影响。 例如，2020 年 4 月，加拿大基因组启动了加拿大 COVID 基因组学网络 (CanCOGeN)，这是一项由 4000 万美元资金支持的新成立计划。 在加拿大基因组的领导下，CanCOGeN 将与六个区域基因组中心、国家和省级公共卫生实验室、通过 CGEn 的基因组测序中心、医院、大学和私营部门合作，将在加拿大提供基于基因组的 COVID-19 研究。我们计划扩大我们的研究。

此外，与美国国家人类基因组研究所 (NHGRI) 一样，我们在支持与解码人类基因组相关的研究的同时，还资助基因组在健康和疾病中的结构、功能和作用的研究。还有各种政府机构， 此外，这些组织还支持对基因组研究的伦理、法律和社会影响的研究。

竞争格局

DNA 测序市场竞争激烈，由几家大型企业组成。 Agilent Technologies Inc.、Bio-Rad Laboratories Inc.、Danaher Corporation、Eurofins Scientific、F. Hoffmann-La Roche、Illumina Inc.、Merck KGaA、Pacific Biosciences of California Inc、PerkinElmer Inc、Thermo Fisher Scientific Inc.等公司。在 DNA 测序市场占有相当大的份额。 这些公司正在努力满足不断增长的消费者需求，并在生产、分销和全面质量控制方面进行了大量投资，以扩大其产品组合。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 调查结果
  • 调查假设
  • 本次调查的范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • DNA 测序技术不断进步
    • 在临床诊断和药物发现方面的应用有所增加
    • 增加研发投资
  • 市场製约因素
    • 复杂的数据解释和缺乏熟练的专业人员
    • 法律和道德问题
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（按价值计算的市场规模：百万美元）

  • 产品类型
    • 设备
    • 耗材（试剂盒、试剂）
    • 其他产品类型
  • 测序类型
    • 桑格测序
    • 下一代测序
    • 其他排序类型
  • 应用领域
    • 诊断
    • 个性化医疗
    • 其他应用
  • 最终用户
    • 医院和医疗保健机构
    • 学术和研究机构
    • 製药和生物技术公司
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东和非洲
      • 海湾合作委员会
      • 南非
      • 其他中东和非洲地区
    • 南美洲地区
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Agilent Technologies Inc.
    • Bio-Rad Laboratories Inc.
    • Danaher Corporation（Integrated DNA Technologies Inc.）
    • F. Hoffmann-La Roche Ltd
    • Illumina Inc.
    • Merck KGaA
    • PerkinElmer Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN
    • Macrogen Inc.
    • Myriad Genetics Inc.
    • Intrexon Bioinformatics Germany GmbH
    • Eurofins Scientific
    • Hamilton Thorne Biosciences
    • Pacific Biosciences of California Inc.

第7章 市场机会与今后动向

简介目录
Product Code: 66764

The DNA sequencing market was valued at approximately USD 10,409.54 million in 2021, and it is expected to reach USD 23,885.65 million by 2027, registering a CAGR of 18.61% during the forecast period (2022-2027).

The COVID-19 pandemic had a positive impact on the market studied, as it increased the demand for DNA sequencing technology in the development of therapeutics and diagnostics. For instance, in August 2020, the Helix COVID-19 NGS test was authorized by FDA under an Emergency Use Authorization (EUA) for use only by Helix Laboratory; it is an amplicon-based next-generation sequencing (NGS) test intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in upper respiratory specimens from individuals suspected of COVID-19 infection. Hence, owing to the increasing DNA sequencing-based research and development activities in the development of diagnostic tools or effective therapeutics for COVID-19, the market is likely to continue its significant growth rate during the forecast period.

Certain factors driving the market growth include the rise in technological advancements in DNA sequencing, increasing application in clinical diagnosis and drug discovery, and growing investments in R&D. DNA sequencing has its applications in diagnostics, personalized medicine, biomarkers, forensics, reproductive health, and other applications. ] DNA sequencing technology holds great potential in the clinical research and development of cancer diagnostics and therapeutics. Recently, the next-generation sequencing (NGS) technology has demonstrated its capacity as a high-throughput and affordable approach to the identification and characterization of clinically actionable genetic variants across numerous genes at an exceptional speed in a single test. According to a research article by Hong-Yan Liu et al., published in the Scientific Reports Journal 2019, it has been estimated that 80% of rare diseases are genetic in origin, and thus, genome sequencing-based diagnosis offers a promising alternative for rare-disease management, which is expected to have a positive impact on the market. Therefore, the increasing application of DNA sequencing in clinical diagnosis and drug discovery is expected to drive the market growth over the forecast period.

The technological advancements in sequencing, from 2D sequencing in the 1970s to DNA sequencing, have come a long way. In recent years, platforms such as Illumina/ Solexa, ABI/ SOLiD, 454/Roche, and Helicos have provided unique prospects for high-throughput functional genomic research. Moreover, biologists and informatics experts have been focusing on the development of better genomes, one made possible by newer sequencing technologies, novel methods for locating sequences on chromosomes, and improved software for DNA sequencing.

In addition, the next-generation sequencing (NGS) technology has been gaining popularity as a routine clinical diagnostic test, particularly with the COVID-19 pandemic, which has had a positive impact on the market. Thus, the increasing advancements in DNA sequencing technologies are contributing to the growth of the market studied.

Key Market Trends

The Next-generation Sequencing Segment is Expected to Dominate the Market During the Forecasted Period

The next-generation sequencing segment is being driven by factors such as the increasing applications of NGS, speed, cost, accuracy, efficient replacement of traditional technologies, and drug discovery applications demanding NGS technology. The advantage of this technology is that it is significantly cheaper, quicker, and needs significantly lesser DNA, which helps in the overall growth of the segment.

With the COVID-19 pandemic, there has been an increase in the adoption of next-generation sequencing technology in the diagnostics of infections, owing to its high efficiency and accuracy. In June 2020, the FDA issued an emergency use authorization to Ilumina Inc. for the product COVIDSeq Test, the first COVID-19 diagnostic test utilizing next-generation sequencing technology. The advantage of using a next-generation sequencing test is that it can generate information about the genomic sequence of the virus present in a sample along with detecting the presence of the virus in the sample. This genomic information can be used for research purposes, thus supporting the growth of the market.

There are various technological advancements in the field of medicine that are growing at a rapid pace and have led to the development of personalized medicine. There are a huge number of applications of next-generation sequencing in personalized medicine. In May 2020, the Swedish biotechnology company CARTANA launched an expanded range of In Situ Sequencing kits for high throughput single-cell gene expression mapping. In October 2020, Bio-Rad Laboratories Inc. announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit, a novel approach to RNA-Seq library preparation. Thus, the development of personalized medicine has opened many avenues for the application of NGS, which could accelerate the growth of the segment.

Along with the advantages of and increasing demand for this technology, the launches and advancements are huge boosters to the segment growth. For instance, Thermo Fisher Scientific launched its Ion Torrent Genexus System in November 2019, the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. Hence, owing to the above-mentioned factors, the segment is expected to grow during the forecast period.

North America Dominates the Market, and It is Expected to do the Same During the Forecast Period

North America dominated the market due to the increase in funding and support activities by the government and non-government entities, especially in United States. The increasing adoption of advanced technologies and favorable support from the government and related policies are the primary driving factors for DNA sequencing in the country.

With the rising COVID-19 pandemic, there has been a positive impact on the market growth. For instance, in April 2020, Genome Canada launched the Canadian COVID Genomics Network (CanCOGeN), a newly formed initiative backed by funding of USD 40 million. Led by Genome Canada, in partnership with the six regional Genome Centers, national and provincial public health labs, genome sequencing centers through CGEn, hospitals, universities, and the private sector, CanCOGeN will scale up genomics-based COVID-19 research in Canada.

There are also various government bodies, like the US-based National Human Genome Research Institute (NHGRI), that have been supporting research related to human genome sequencing while funding research related to the genome's structure, function, and role in health and disease. Moreover, these organizations support studies on the ethical, legal, and social implications of genome research.

In December 2020, Illumina Inc. and Harvard Pilgrim Health Care announced a risk-sharing agreement to make whole-genome sequencing (WGS) available to certain Harvard Pilgrim members, effective January 2021. The program will leverage WGS to support faster diagnoses of genetic diseases in children, potentially eliminating the long, costly diagnostic process experienced by many families, with the goal of improving patient outcomes. In February 2020, MGI, part of the global genomics leader BGI Group, announced the commercial availability of its sequencing instruments and reagent kits in United States.

In November 2019, Thermo Fisher Scientific announced the launch of its Ion Torrent Genexus System, which is the first fully integrated, next-generation sequencing (NGS) platform featuring an automated specimen-to-report workflow that delivers results economically in a single day. ​ Hence, owing to these factors, the DNA sequencing market is expected to be one of the largest in the future.​

Competitive Landscape

The DNA sequencing market is highly competitive and consists of a few major players. Companies like Agilent Technologies Inc., Bio-Rad Laboratories Inc., Danaher Corporation, Eurofins Scientific, F. Hoffmann-La Roche, Illumina Inc., Merck KGaA, Pacific Biosciences of California Inc., PerkinElmer Inc., and Thermo Fisher Scientific Inc., among others, hold substantial shares in the DNA sequencing market. These companies are making efforts to address the rising consumer demand and are significantly investing in production, distribution, and total quality management for the expansion of their portfolios.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Technological Advancements in DNA Sequencing
    • 4.2.2 Increasing Application in Clinical Diagnosis and Drug Discovery
    • 4.2.3 Growing Investments in R&D
  • 4.3 Market Restraints
    • 4.3.1 Interpretation of Complex Data and Lack of Skilled Professionals
    • 4.3.2 Legal and Ethical Issues
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 Product Type
    • 5.1.1 Instruments
    • 5.1.2 Consumables (Kits and Reagents)
    • 5.1.3 Other Product Types
  • 5.2 Sequencing Type
    • 5.2.1 Sanger Sequencing
    • 5.2.2 Next-generation Sequencing
    • 5.2.3 Other Sequencing Types
  • 5.3 Application
    • 5.3.1 Diagnostics
    • 5.3.2 Personalized Medicine
    • 5.3.3 Other Applications
  • 5.4 End User
    • 5.4.1 Hospitals and Healthcare Organizations
    • 5.4.2 Academics and Research Institutions
    • 5.4.3 Pharmaceutical and Biotechnology Companies
    • 5.4.4 Other End Users
  • 5.5 Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Agilent Technologies Inc.
    • 6.1.2 Bio-Rad Laboratories Inc.
    • 6.1.3 Danaher Corporation (Integrated DNA Technologies Inc.)
    • 6.1.4 F. Hoffmann-La Roche Ltd
    • 6.1.5 Illumina Inc.
    • 6.1.6 Merck KGaA
    • 6.1.7 PerkinElmer Inc.
    • 6.1.8 Thermo Fisher Scientific Inc.
    • 6.1.9 QIAGEN
    • 6.1.10 Macrogen Inc.
    • 6.1.11 Myriad Genetics Inc.
    • 6.1.12 Intrexon Bioinformatics Germany GmbH
    • 6.1.13 Eurofins Scientific
    • 6.1.14 Hamilton Thorne Biosciences
    • 6.1.15 Pacific Biosciences of California Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS